Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,525 | -5,320 | -3,452 | -15,014 | -9,838 |
| Depreciation Amortization | 256 | 175 | 90 | 545 | 509 |
| Accounts payable and accrued liabilities | -436 | -269 | -278 | -16 | -735 |
| Other Working Capital | -474 | -298 | -470 | -1,218 | -1,889 |
| Other Operating Activity | 389 | -110 | -514 | 2,695 | 3,029 |
| Operating Cash Flow | $-7,790 | $-5,822 | $-4,624 | $-13,008 | $-8,924 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 7,214 | 4,280 | 2,869 | 6,869 | 3,772 |
| PPE Investments | -59 | -38 | -31 | 81 | 109 |
| Other Investing Activity | 902 | 0 | 335 | 2,109 | 1,820 |
| Investing Cash Flow | $8,057 | $4,242 | $3,173 | $9,059 | $5,701 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 549 | 197 | 197 | 6,454 | 5,193 |
| Financing Cash Flow | $549 | $197 | $197 | $6,454 | $5,193 |
| Beginning Cash Position | 3,731 | 3,731 | 3,731 | 1,226 | 1,226 |
| End Cash Position | 4,547 | 2,348 | 2,477 | 3,731 | 3,196 |
| Net Cash Flow | $816 | $-1,383 | $-1,254 | $2,505 | $1,970 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,790 | -5,822 | -4,624 | -13,008 | -8,924 |
| Capital Expenditure | -60 | -39 | -32 | -103 | -68 |
| Free Cash Flow | -7,850 | -5,861 | -4,656 | -13,111 | -8,992 |